skip to navigation skip to content
 

Accelerate Plus

These ventures have been with Accelerate Cambridge for over six months and are looking at raising their seed round.

angioClast

angioClast is a UK and Ireland-based biotech startup company led by a group of young professionals from the University of Cambridge. We are developing products targeting Glioblastoma Multiforme, the most aggressive and incurable brain cancer, from both diagnostic and therapeutic perspectives. 

angioClast's business model is to license out a patent from the National Institute of Health through the NIH start-up exclusive licensing agreement, and harness the value of newly identified biomarkers of cancer-associated blood vessels. Antibodies against these markers form the basis for antibody-drug conjugates (ADCs) that will deliver and release drugs against glioblastoma in a highly specific manner. Detection of glioblastoma will be made possible through further formulation of the antibodies into an ELISA-based diagnostic toolkit that is more accurate and less invasive than conventional clinical practices.

Through innovative products for early detection and targeted therapy, angioClast's vision is to make Glioblastoma Multiforme a more treatable disease.

AngioClast logo

Anvil

 Anvil is a tool that takes the pain out of software development, without sacrificing power. Companies are best placed to know their own businesses and develop their own business process tools, but developing web applications is hugely slow and complicated. Anvil's visual designer, simple Python code environment and "batteries-included" philosophy makes business application development faster, easier and more agile.

Visit the Anvil website

Anvil logo

Capito Systems

Capito Systems (est. 2012), also trading as capito.ai, specialises in the contextual understanding of natural language (NLU). We have built a high performance NLU cloud platform that delivers application-specific semantic understanding of free-form voice and text inputs at speed and scale. Applications include intelligent voice control, conversational interfaces like chat bots, and semantic search. Our technology is platform-independent and easy to integrate via our APIs. We are able to ‘bootstrap’ NLU models quickly using the latest machine learning techniques coupled with our streamlined development workflows in support of rapid prototyping & testing. Unlike other NLP/NLU solutions, including the “open developer platforms” offered by major players like Amazon, Microsoft and Facebook, ours is a premium NLU product customised for each use case by our in-house experts, as we seek to develop long-term relationships with our clients.

Visit the Capito Systems website

Capito.ai logo

Citrecycle

Citrecycle has adapted new technology that unlocks the full potential of the lead-acid batteries (LAB) recycling industry in developing countries whilst simultaneously maintaining focus on development objectives. Citrecycle uses hydro metallurgy to recycle LAB in a safe, clean and sustainable way. We will utilise local independent co-operatives to collect the supply for recycling. Our ability to extract more value from each battery enables us to buy batteries at greater value than that that can be obtained from informal recycling. We can double the amount paid per battery, and still remain profitable, to ensure Citrecycle can absorb the informal recycling sector. Our process then recycles the batteries cleanly, using a Carbon neutral process. Hydro metallurgy inherently restricts poisonous emissions, slashes direct and indirect CO2 and operates profitably at smaller scales, 1000 tons per year rather than 50,000 - the size at which adequate pollution controls are considered to be cost effective. The scalable nature means that small, community directed plants will not replace the informal recyclers industry, but empower local communities by providing a cleaner and safer way to make money through localised employment. The replacement of informal LAB recycling practices with a safe provision that does not involve dangerous emissions, eradicates exposure of local communities and the environment to lead contamination, eliminating the risk of lead poisoning. The need for strong infrastructure for mass collection is overcome, sound legislation is unnecessary to regulate safety and exposure of local communities and the environment to lead contamination is prevented. Pollution, lead poisoning and fatality are replaced by job opportunities, prosperity, cleanliness and health.

info@citrecycle.co.uk

Watch the CitreCycle team in discussion with Luther Phillips

Citrecycle logo

cThings

cThings Limited is an IoT solution provider specifically developing products for social housing, elderly care and the private rental markets. Our products enable landlords and carers to have complete visibility of their properties and their associated assets to ensure the best quality of service for their residents.

cThings has developed a truly revolutionary suite of modular hardware which enables our clients to monitor, control and engage with their properties in real time. The flexibility of our hardware enables cThings to adapt its product set to meet specific customers requirements with minimal time and expense.

Combining our innovative hardware with event-based alerts and data analytics from the cThings cloud provides customers with valuable insights, allowing them to reduce costs, provide an improved resident experience and safe guard vulnerable residents.

cThings enables our customers to provide better and safer homes through technology.

cThings logo

Elpis BioMed

Elpis BioMed aims to become a leading, global supplier of in vitro cell types for academic research and commercial drug discovery and development purposes. The cells could provide an alternative to the limited supply of primary cells and replace animal studies in other cases. Elpis Biomed’s proprietary technology allows it rapidly to generate highly mature, differentiated cell types at unmatched purity. The process is scalable with the potential to expand product offering with additional cell-types in the neuro-mesoderm focus area. Initial products will be cortical neurons, oligodendrocytes and skeletal muscle cells.

LIFNanoRx

LIFNanoRx is a nano-bio-med company focused on treatment of Multiple Sclerosis (MS), a disabling incurable auto-immune inflammatory disease of the central nervous system (CNS) commonly affecting young adults. LIF - short for Leukaemia Inhibitory Factor - is a critical stem cell factor that has unique biological properties: these not only promote tissue repair but also suppress disease-linked inflammation. These therapeutic properties are harnessed in LIFNanoRx's targeted medicinal nanoparticle - "LIFNano" - providing a safe, cell-free, drug-free and potentially curative approach to MS. The technology is patented and LIFNanoRx holds worldwide exclusive licence in exploitation of LIF using their NanoMed platform technology.

LIFNanoRx logo

PHARMeNABLE

PharmEnable supports early drug-discovery programs by providing a rapid, cost-efficient and effective platform to identify new chemical starting points for drug development.

Visit the PHARMeNABLE website

Pharmenable logo

Satavia

 Satavia is an analytics and visualisation company that develops bespoke environmental awareness solutions for all segments of the aviation market. We aim to provide ‘personalised environmental health management’ for aircraft and unmanned aerial systems to reinforce the safety and reliability of flight operations, while minimising unanticipated maintenance costs. Satavia delivers live aircraft-centric metrics for a range of environmental threats and combines expertise in aeronautical meteorology, big data and analytics, and 3-D visualisation technology.

Satavia logo

SmartBell

SmartBell offers a simple way to implement a fully integrated and automated solution for livestock management, including livestock status and distress alerts, herd analysis and customised farm management reports. Using advanced analytics on data gathered from cattle wearables, information from individual farms is aggregated across regional farms to better understand land utilisation and promote proven efficiencies. Long-term weather trends and predictions, such as a forecasted droughts, are factored into this data to develop predictive analysis and planning of land and resources for optimising yield.

Watch the SmartBell team in discussion with Luther Phillips

SmartBell logo

Solidi

Digital currencies represent the future of global on and offline payments. They are fast, cheap, convenient, irreversible and do not rely on a central authority to oversee and run them. They are not limited by geography or nationality and enable payments to be made between people on opposite sides of the globe in seconds lowering the barrier to global business and travel. At the same time, their design and cost structure enable the 2.5 billion unbanked adults worldwide (over 60 per cent of the world's adult population) to finally have a method of transacting and saving out with the cash economy. 

Solidi aims to make buying, selling, spending and holding digital currencies as easy as using cash, while retaining all the benefits of an unforgeable digital token. 

We provide a UK-based, person-to-person matching exchange tightly integrated with the UK Faster Payments System, a mobile app to buy and sell on the exchange, monthly savings options, and an easy to use mobile wallet which supports repurchasing digital currencies as you spend them. 

We are regulated by HMRC as a Bureau de Change and are actively pursuing registration with the FCA as a Money Services Business. Our founders have substantial experience in FinTech and mobile having worked at major investment banks and mobile technology firms.

contact@solidi.co

Visit the Solidi website

Solidi logo

SPIREA

SPIREA is a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

The technology is based on biodegradable polymeric formulations of a combination of drugs for targeted and sustained release that will ultimately improve the efficacy and safety of treatments and patient compliance and comfort. This means a simpler, safer and more effective treatment for various diseases and a pioneering strategy in the management of diseases by combination therapy.

SPIREA aims to establish the polymer platform as a major player in the drug delivery space by partnering with pharmaceutical and biotech companies.

SPIREA logo

Swift Molecular Diagnostics

Swift Molecular Diagnostics have created a novel technology that allows the development of self-contained diagnostic devices for the fast, accurate and low-cost genetic detection that do not require laboratory facilities or trained personnel.

We have filed the patent application of our technology and we aim in the first instance to implement our technology to detect antibiotic resistance from patients, allowing the effective treatment of bacterial infections and fast response in acute cases such as bacteraemia and septicaemia.

Watch the Swift Molecular Diagnostics team in discussion with Luther Phillips

SwiftDX